PDF herunterladen
Semin Neurol 2015; 35(04): 407-423
DOI: 10.1055/s-0035-1558981
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Inherited Neuropathies

Vera Fridman
1   Department of Neurology, Neuromuscular Diagnostic Center, Massachusetts General Hospital, Boston, Massachusetts
,
M. M. Reilly
2   MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
06. Oktober 2015 (online)

    Lizenzen und Reprints

Abstract

Hereditary neuropathies (HNs) are among the most common inherited neurologic disorders and are diverse both clinically and genetically. Recent genetic advances have contributed to a rapid expansion of identifiable causes of HN and have broadened the phenotypic spectrum associated with many of the causative mutations. The underlying molecular pathways of disease have also been better delineated, leading to the promise for potential treatments. This chapter reviews the clinical and biological aspects of the common causes of HN and addresses the challenges of approaching the diagnostic workup of these conditions in a rapidly evolving genetic landscape.

Keywords

hereditary neuropathy - Charcot-Marie-Tooth disease - hereditary sensory and motor neuropathy - hereditary sensory and autonomic neuropathy
 

  • References

  • 1 Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet 1974; 6 (2) 98-118
    PubMedGoogle Scholar
  • 2 Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain 1980; 103 (2) 259-280
    CrossrefPubMedGoogle Scholar
  • 3 Davis CJ, Bradley WG, Madrid R. The peroneal muscular atrophy syndrome: clinical, genetic, electrophysiological and nerve biopsy studies. I. Clinical, genetic and electrophysiological findings and classification. J Genet Hum 1978; 26 (4) 311-349
    PubMedGoogle Scholar
  • 4 Liu L, Zhang R. Intermediate Charcot-Marie-Tooth disease. Neurosci Bull 2014; 30 (6) 999-1009
    CrossrefPubMedGoogle Scholar
  • 5 Saporta AS, Sottile SL, Miller LJ, Feely SM, Siskind CE, Shy ME. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol 2011; 69 (1) 22-33
    CrossrefPubMedGoogle Scholar
  • 6 Brennan KM, Bai Y, Shy ME. Demyelinating CMT-what's known, what's new and what's in store?. Neurosci Lett 2015; 596: 14-26
    CrossrefPubMedGoogle Scholar
  • 7 Fridman V, Bundy B, Reilly MM , et al; on behalf of the Inherited Neuropathies Consortium. CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis. J Neurol Neurosurg Psychiatry 2014;
    PubMedGoogle Scholar
  • 8 Murphy SM, Laura M, Fawcett K , et al. Charcot-Marie-Tooth disease: frequency of genetic subtypes and guidelines for genetic testing. J Neurol Neurosurg Psychiatry 2012; 83 (7) 706-710
    CrossrefPubMedGoogle Scholar
  • 9 England JD, Gronseth GS, Franklin G , et al; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review). Muscle Nerve 2009; 39 (1) 116-125
    CrossrefPubMedGoogle Scholar
  • 10 Shy ME, Jáni A, Krajewski K , et al. Phenotypic clustering in MPZ mutations. Brain 2004; 127 (Pt 2): 371-384
    CrossrefPubMedGoogle Scholar
  • 11 Niemann A, Wagner KM, Ruegg M, Suter U. GDAP1 mutations differ in their effects on mitochondrial dynamics and apoptosis depending on the mode of inheritance. Neurobiol Dis 2009; 36 (3) 509-520
    CrossrefPubMedGoogle Scholar
  • 12 Liu YT, Laurá M, Hersheson J , et al. Extended phenotypic spectrum of KIF5A mutations: from spastic paraplegia to axonal neuropathy. Neurology 2014; 83 (7) 612-619
    CrossrefPubMedGoogle Scholar
  • 13 Bassam BA. Charcot-Marie-Tooth disease variants-classification, clinical, and genetic features and rational diagnostic evaluation. J Clin Neuromuscul Dis 2014; 15 (3) 117-128
    CrossrefPubMedGoogle Scholar
  • 14 Jerath NU, Shy ME. Hereditary motor and sensory neuropathies: understanding molecular pathogenesis could lead to future treatment strategies. Biochim Biophys Acta 2015; 1852 (4) 667-678
    CrossrefPubMedGoogle Scholar
  • 15 Szigeti K, Nelis E, Lupski JR. Molecular diagnostics of Charcot-Marie-Tooth disease and related peripheral neuropathies. Neuromolecular Med 2006; 8 (1–2) 243-254
    PubMedGoogle Scholar
  • 16 Tazir M, Hamadouche T, Nouioua S, Mathis S, Vallat JM. Hereditary motor and sensory neuropathies or Charcot-Marie-Tooth diseases: an update. J Neurol Sci 2014; 347 (1–2) 14-22
    CrossrefPubMedGoogle Scholar
  • 17 Pitceathly RD, Murphy SM, Cottenie E , et al. Genetic dysfunction of MT-ATP6 causes axonal Charcot-Marie-Tooth disease. Neurology 2012; 79 (11) 1145-1154
    CrossrefPubMedGoogle Scholar
  • 18 Houlden H, Reilly MM, Smith S. Pupil abnormalities in 131 cases of genetically defined inherited peripheral neuropathy. Eye (Lond) 2009; 23 (4) 966-974
    CrossrefPubMedGoogle Scholar
  • 19 Houlden H, King RH, Wood NW, Thomas PK, Reilly MM. Mutations in the 5′ region of the myotubularin-related protein 2 (MTMR2) gene in autosomal recessive hereditary neuropathy with focally folded myelin. Brain 2001; 124 (Pt 5): 907-915
    CrossrefPubMedGoogle Scholar
  • 20 Rossor AM, Kalmar B, Greensmith L, Reilly MM. The distal hereditary motor neuropathies. J Neurol Neurosurg Psychiatry 2012; 83 (1) 6-14
    CrossrefPubMedGoogle Scholar
  • 21 Rossor AM, Murphy S, Reilly MM. Knee bobbing in Charcot-Marie-Tooth disease. Pract Neurol 2012; 12 (3) 182-183
    CrossrefPubMedGoogle Scholar
  • 22 Houlden H, King R, Blake J , et al. Clinical, pathological and genetic characterization of hereditary sensory and autonomic neuropathy type 1 (HSAN I). Brain 2006; 129 (Pt 2): 411-425
    CrossrefPubMedGoogle Scholar
  • 23 Michell AW, Laura M, Blake J , et al. GJB1 gene mutations in suspected inflammatory demyelinating neuropathies not responding to treatment. J Neurol Neurosurg Psychiatry 2009; 80 (6) 699-700
    CrossrefPubMedGoogle Scholar
  • 24 Rossor AM, Polke JM, Houlden H, Reilly MM. Clinical implications of genetic advances in Charcot-Marie-Tooth disease. Nat Rev Neurol 2013; 9 (10) 562-571
    CrossrefPubMedGoogle Scholar
  • 25 Burns J, Ouvrier R, Estilow T , et al. Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability. Ann Neurol 2012; 71 (5) 642-652
    CrossrefPubMedGoogle Scholar
  • 26 Murphy SM, Herrmann DN, McDermott MP , et al. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst 2011; 16 (3) 191-198
    CrossrefPubMedGoogle Scholar
  • 27 Shy ME, Blake J, Krajewski K , et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 2005; 64 (7) 1209-1214
    CrossrefPubMedGoogle Scholar
  • 28 Ishigami N, Kondo M, Nakagawa M. [Case of Charcot-Marie-Tooth disease type 1A with increased cerebrospinal fluid proteins and nerve root hypertrophy]. Rinsho Shinkeigaku 2008; 48 (6) 419-421
    CrossrefPubMedGoogle Scholar
  • 29 Liao JP, Waclawik AJ. Nerve root hypertrophy in CMT type 1A. Neurology 2004; 62 (5) 783
    CrossrefPubMedGoogle Scholar
  • 30 Latour P, Gonnaud PM, Ollagnon E , et al. SIMPLE mutation analysis in dominant demyelinating Charcot-Marie-Tooth disease: three novel mutations. J Peripher Nerv Syst 2006; 11 (2) 148-155
    CrossrefPubMedGoogle Scholar
  • 31 Wright CF, Middleton A, Burton H , et al. Policy challenges of clinical genome sequencing. BMJ 2013; 347: f6845
    CrossrefPubMedGoogle Scholar
  • 32 Blair IP, Nash J, Gordon MJ, Nicholson GA. Prevalence and origin of de novo duplications in Charcot-Marie-Tooth disease type 1A: first report of a de novo duplication with a maternal origin. Am J Hum Genet 1996; 58 (3) 472-476
    PubMedGoogle Scholar
  • 33 Thomas PK, Marques Jr W, Davis MB , et al. The phenotypic manifestations of chromosome 17p11.2 duplication. Brain 1997; 120 (Pt 3): 465-478
    CrossrefPubMedGoogle Scholar
  • 34 Pelayo-Negro AL, Carr AS, Laura M, Skorupinska M, Reilly MM. An observational study of asymmetry in CMT1A. J Neurol Neurosurg Psychiatry 2015; 86 (5) 589-590
    CrossrefPubMedGoogle Scholar
  • 35 Bamford NS, White KK, Robinett SA, Otto RK, Gospe Jr SM. Neuromuscular hip dysplasia in Charcot-Marie-Tooth disease type 1A. Dev Med Child Neurol 2009; 51 (5) 408-411
    CrossrefPubMedGoogle Scholar
  • 36 Pareyson D, Reilly MM, Schenone A , et al; CMT-TRIAAL; CMT-TRAUK groups. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 2011; 10 (4) 320-328
    CrossrefPubMedGoogle Scholar
  • 37 Adlkofer K, Frei R, Neuberg DH, Zielasek J, Toyka KV, Suter U. Heterozygous peripheral myelin protein 22-deficient mice are affected by a progressive demyelinating tomaculous neuropathy. J Neurosci 1997; 17 (12) 4662-4671
    PubMedGoogle Scholar
  • 38 Fortun J, Verrier JD, Go JC, Madorsky I, Dunn WA, Notterpek L. The formation of peripheral myelin protein 22 aggregates is hindered by the enhancement of autophagy and expression of cytoplasmic chaperones. Neurobiol Dis 2007; 25 (2) 252-265
    CrossrefPubMedGoogle Scholar
  • 39 Burns J, Ouvrier RA, Yiu EM , et al. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol 2009; 8 (6) 537-544
    CrossrefPubMedGoogle Scholar
  • 40 Lewis RA, McDermott MP, Herrmann DN , et al; Muscle Study Group. High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol 2013; 70 (8) 981-987
    CrossrefPubMedGoogle Scholar
  • 41 Passage E, Norreel JC, Noack-Fraissignes P , et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004; 10 (4) 396-401
    CrossrefPubMedGoogle Scholar
  • 42 Chance PF, Alderson MK, Leppig KA , et al. DNA deletion associated with hereditary neuropathy with liability to pressure palsies. Cell 1993; 72 (1) 143-151
    CrossrefPubMedGoogle Scholar
  • 43 Andersson PB, Yuen E, Parko K, So YT. Electrodiagnostic features of hereditary neuropathy with liability to pressure palsies. Neurology 2000; 54 (1) 40-44
    CrossrefPubMedGoogle Scholar
  • 44 Chance PF. Inherited focal, episodic neuropathies: hereditary neuropathy with liability to pressure palsies and hereditary neuralgic amyotrophy. Neuromolecular Med 2006; 8 (1–2) 159-174
    CrossrefPubMedGoogle Scholar
  • 45 Li J, Krajewski K, Shy ME, Lewis RA. Hereditary neuropathy with liability to pressure palsy: the electrophysiology fits the name. Neurology 2002; 58 (12) 1769-1773
    CrossrefPubMedGoogle Scholar
  • 46 Earle N, Zochodne DW. Is carpal tunnel decompression warranted for HNPP?. J Peripher Nerv Syst 2013; 18 (4) 331-335
    CrossrefPubMedGoogle Scholar
  • 47 Russo M, Laurá M, Polke JM , et al. Variable phenotypes are associated with PMP22 missense mutations. Neuromuscul Disord 2011; 21 (2) 106-114
    CrossrefPubMedGoogle Scholar
  • 48 Shy ME. Peripheral neuropathies caused by mutations in the myelin protein zero. J Neurol Sci 2006; 242 (1–2) 55-66
    CrossrefPubMedGoogle Scholar
  • 49 Saifee TA, Pareés I, Kassavetis P , et al. Tremor in Charcot-Marie-Tooth disease: No evidence of cerebellar dysfunction. Clin Neurophysiol 2015;
    PubMedGoogle Scholar
  • 50 Filbin MT, Walsh FS, Trapp BD, Pizzey JA, Tennekoon GI. Role of myelin P0 protein as a homophilic adhesion molecule. Nature 1990; 344 (6269) 871-872
    CrossrefPubMedGoogle Scholar
  • 51 Suter U, Scherer SS. Disease mechanisms in inherited neuropathies. Nat Rev Neurosci 2003; 4 (9) 714-726
    CrossrefPubMedGoogle Scholar
  • 52 Shy ME. Therapeutic strategies for the inherited neuropathies. Neuromolecular Med 2006; 8 (1–2) 255-278
    CrossrefPubMedGoogle Scholar
  • 53 Colby J, Nicholson R, Dickson KM , et al. PMP22 carrying the trembler or trembler-J mutation is intracellularly retained in myelinating Schwann cells. Neurobiol Dis 2000; 7 (6 Pt B): 561-573
    CrossrefPubMedGoogle Scholar
  • 54 Yum SW, Kleopa KA, Shumas S, Scherer SS. Diverse trafficking abnormalities of connexin32 mutants causing CMTX. Neurobiol Dis 2002; 11 (1) 43-52
    CrossrefPubMedGoogle Scholar
  • 55 Egan ME, Pearson M, Weiner SA , et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004; 304 (5670) 600-602
    CrossrefPubMedGoogle Scholar
  • 56 Khajavi M, Inoue K, Wiszniewski W, Ohyama T, Snipes GJ, Lupski JR. Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathy-causing myelin protein zero-truncating mutants. Am J Hum Genet 2005; 77 (5) 841-850
    CrossrefPubMedGoogle Scholar
  • 57 Patzkó A, Bai Y, Saporta MA , et al. Curcumin derivatives promote Schwann cell differentiation and improve neuropathy in R98C CMT1B mice. Brain 2012; 135 (Pt 12): 3551-3566
    CrossrefPubMedGoogle Scholar
  • 58 Scherer SS, Kleopa KA. X-linked Charcot-Marie-Tooth disease. J Peripher Nerv Syst 2012; 17 (Suppl. 03) 9-13
    CrossrefPubMedGoogle Scholar
  • 59 Shy ME, Siskind C, Swan ER , et al. CMT1X phenotypes represent loss of GJB1 gene function. Neurology 2007; 68 (11) 849-855
    CrossrefPubMedGoogle Scholar
  • 60 Bergoffen J, Scherer SS, Wang S , et al. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science 1993; 262 (5142) 2039-2042
    CrossrefPubMedGoogle Scholar
  • 61 Siskind CE, Murphy SM, Ovens R, Polke J, Reilly MM, Shy ME. Phenotype expression in women with CMT1X. J Peripher Nerv Syst 2011; 16 (2) 102-107
    CrossrefPubMedGoogle Scholar
  • 62 Kleopa KA, Scherer SS. Molecular genetics of X-linked Charcot-Marie-Tooth disease. Neuromolecular Med 2006; 8 (1–2) 107-122
    CrossrefPubMedGoogle Scholar
  • 63 Hahn AF, Brown WF, Koopman WJ, Feasby TE. X-linked dominant hereditary motor and sensory neuropathy. Brain 1990; 113 (Pt 5): 1511-1525
    CrossrefPubMedGoogle Scholar
  • 64 Lee MJ, Nelson I, Houlden H , et al. Six novel connexin32 (GJB1) mutations in X-linked Charcot-Marie-Tooth disease. J Neurol Neurosurg Psychiatry 2002; 73 (3) 304-306
    CrossrefPubMedGoogle Scholar
  • 65 Sato K, Kubo S, Fujii H , et al. Diffusion tensor imaging and magnetic resonance spectroscopy of transient cerebral white matter lesions in X-linked Charcot-Marie-Tooth disease. J Neurol Sci 2012; 316 (1–2) 178-180
    CrossrefPubMedGoogle Scholar
  • 66 Bondurand N, Girard M, Pingault V, Lemort N, Dubourg O, Goossens M. Human Connexin 32, a gap junction protein altered in the X-linked form of Charcot-Marie-Tooth disease, is directly regulated by the transcription factor SOX10. Hum Mol Genet 2001; 10 (24) 2783-2795
    CrossrefPubMedGoogle Scholar
  • 67 Murphy SM, Ovens R, Polke J , et al. X inactivation in females with X-linked Charcot-Marie-Tooth disease. Neuromuscul Disord 2012; 22 (7) 617-621
    CrossrefPubMedGoogle Scholar
  • 68 Nicholson G, Nash J. Intermediate nerve conduction velocities define X-linked Charcot-Marie-Tooth neuropathy families. Neurology 1993; 43 (12) 2558-2564
    CrossrefPubMedGoogle Scholar
  • 69 Scherer SS, Deschênes SM, Xu YT, Grinspan JB, Fischbeck KH, Paul DL. Connexin32 is a myelin-related protein in the PNS and CNS. J Neurosci 1995; 15 (12) 8281-8294
    CrossrefPubMedGoogle Scholar
  • 70 Kleopa KA, Abrams CK, Scherer SS. How do mutations in GJB1 cause X-linked Charcot-Marie-Tooth disease?. Brain Res 2012; 1487: 198-205
    CrossrefPubMedGoogle Scholar
  • 71 Menichella DM, Goodenough DA, Sirkowski E, Scherer SS, Paul DL. Connexins are critical for normal myelination in the CNS. J Neurosci 2003; 23 (13) 5963-5973
    PubMedGoogle Scholar
  • 72 Miller LJ, Saporta AS, Sottile SL, Siskind CE, Feely SM, Shy ME. Strategy for genetic testing in Charcot-Marie-disease. Acta Myologica: Myopathies and Cardiomyopathies 2011; 30 (2) 109-116
    PubMedGoogle Scholar
  • 73 Bombelli F, Stojkovic T, Dubourg O , et al. Charcot-Marie-Tooth disease type 2A: from typical to rare phenotypic and genotypic features. JAMA Neurol 2014; 71 (8) 1036-1042
    CrossrefPubMedGoogle Scholar
  • 74 Feely SM, Laura M, Siskind CE , et al. MFN2 mutations cause severe phenotypes in most patients with CMT2A. Neurology 2011; 76 (20) 1690-1696
    CrossrefPubMedGoogle Scholar
  • 75 Rojo M, Legros F, Chateau D, Lombès A. Membrane topology and mitochondrial targeting of mitofusins, ubiquitous mammalian homologs of the transmembrane GTPase Fzo. J Cell Sci 2002; 115 (Pt 8): 1663-1674
    PubMedGoogle Scholar
  • 76 Boaretto F, Vettori A, Casarin A , et al. Severe CMT type 2 with fatal encephalopathy associated with a novel MFN2 splicing mutation. Neurology 2010; 74 (23) 1919-1921
    CrossrefPubMedGoogle Scholar
  • 77 Brockmann K, Dreha-Kulaczewski S, Dechent P , et al. Cerebral involvement in axonal Charcot-Marie-Tooth neuropathy caused by mitofusin2 mutations. J Neurol 2008; 255 (7) 1049-1058
    CrossrefPubMedGoogle Scholar
  • 78 Chung KW, Kim SB, Park KD , et al. Early onset severe and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2 (MFN2) mutations. Brain 2006; 129 (Pt 8): 2103-2118
    CrossrefPubMedGoogle Scholar
  • 79 Züchner S, Vance JM. Molecular genetics of autosomal-dominant axonal Charcot-Marie-Tooth disease. Neuromolecular Med 2006; 8 (1–2) 63-74
    CrossrefPubMedGoogle Scholar
  • 80 Calvo J, Funalot B, Ouvrier RA , et al. Genotype-phenotype correlations in Charcot-Marie-Tooth disease type 2 caused by mitofusin 2 mutations. Arch Neurol 2009; 66 (12) 1511-1516
    PubMedGoogle Scholar
  • 81 de Brito OM, Scorrano L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature 2008; 456 (7222) 605-610
    CrossrefPubMedGoogle Scholar
  • 82 Baloh RH, Schmidt RE, Pestronk A, Milbrandt J. Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations. J Neurosci 2007; 27 (2) 422-430
    CrossrefPubMedGoogle Scholar
  • 83 Detmer SA, Chan DC. Complementation between mouse Mfn1 and Mfn2 protects mitochondrial fusion defects caused by CMT2A disease mutations. J Cell Biol 2007; 176 (4) 405-414
    CrossrefPubMedGoogle Scholar
  • 84 Tazir M, Bellatache M, Nouioua S, Vallat JM. Autosomal recessive Charcot-Marie-Tooth disease: from genes to phenotypes. J Peripher Nerv Syst 2013; 18 (2) 113-129
    CrossrefPubMedGoogle Scholar
  • 85 Roberts RC, Peden AA, Buss F , et al. Mistargeting of SH3TC2 away from the recycling endosome causes Charcot-Marie-Tooth disease type 4C. Hum Mol Genet 2010; 19 (6) 1009-1018
    CrossrefPubMedGoogle Scholar
  • 86 Nicholson G, Ouvrier R. GDAP1 mutations in CMT4: axonal and demyelinating phenotypes?: The exception “proves the rule”. Neurology 2002; 59 (12) 1835-1836
    CrossrefPubMedGoogle Scholar
  • 87 Rotthier A, Baets J, De Vriendt E , et al. Genes for hereditary sensory and autonomic neuropathies: a genotype-phenotype correlation. Brain 2009; 132 (Pt 10): 2699-2711
    CrossrefPubMedGoogle Scholar
  • 88 Rotthier A, Penno A, Rautenstrauss B , et al. Characterization of two mutations in the SPTLC1 subunit of serine palmitoyltransferase associated with hereditary sensory and autonomic neuropathy type I. Hum Mutat 2011; 32 (6) E2211-E2225
    CrossrefPubMedGoogle Scholar
  • 89 Denny-Brown D. Hereditary sensory radicular neuropathy. J Neurol Neurosurg Psychiatry 1951; 14 (4) 237-252
    CrossrefPubMedGoogle Scholar
  • 90 Fridman V, Oaklander AL, David WS , et al. Natural history and biomarkers in hereditary sensory neuropathy type 1. Muscle Nerve 2015; 51 (4) 489-495
    CrossrefPubMedGoogle Scholar
  • 91 Auer-Grumbach M. Hereditary sensory neuropathy type I. Orphanet J Rare Dis 2008; 3: 7
    CrossrefPubMedGoogle Scholar
  • 92 Eichler FS, Hornemann T, McCampbell A , et al. Overexpression of the wild-type SPT1 subunit lowers desoxysphingolipid levels and rescues the phenotype of HSAN1. J Neurosci 2009; 29 (46) 14646-14651
    CrossrefPubMedGoogle Scholar
  • 93 Penno A, Reilly MM, Houlden H , et al. Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. J Biol Chem 2010; 285 (15) 11178-11187
    CrossrefPubMedGoogle Scholar
  • 94 Garofalo K, Penno A, Schmidt BP , et al. Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. J Clin Invest 2011; 121 (12) 4735-4745
    CrossrefPubMedGoogle Scholar
  • 95 Bertea M, Rütti MF, Othman A , et al. Deoxysphingoid bases as plasma markers in diabetes mellitus. Lipids Health Dis 2010; 9: 84
    CrossrefPubMedGoogle Scholar
  • 96 Othman A, Bianchi R, Alecu I , et al. Lowering plasma 1-deoxysphingolipids improves neuropathy in diabetic rats. Diabetes 2015; 64 (3) 1035-1045
    CrossrefPubMedGoogle Scholar
  • 97 d'Ydewalle C, Krishnan J, Chiheb DM , et al. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat Med 2011; 17 (8) 968-974
    CrossrefPubMedGoogle Scholar
  • 98 Sereda MW, Meyer zu Hörste G, Suter U, Uzma N, Nave KA. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 2003; 9 (12) 1533-1537
    CrossrefPubMedGoogle Scholar
  • 99 Piscosquito G, Reilly MM, Schenone A , et al; CMT-TRIAAL & CMT-TRAUK Group. Is overwork weakness relevant in Charcot-Marie-Tooth disease?. J Neurol Neurosurg Psychiatry 2014; 85 (12) 1354-1358
    CrossrefPubMedGoogle Scholar
  • 100 Ramdharry GM, Day BL, Reilly MM, Marsden JF. Hip flexor fatigue limits walking in Charcot-Marie-Tooth disease. Muscle Nerve 2009; 40 (1) 103-111
    CrossrefPubMedGoogle Scholar
  • 101 Boentert M, Knop K, Schuhmacher C, Gess B, Okegwo A, Young P. Sleep disorders in Charcot-Marie-Tooth disease type 1. J Neurol Neurosurg Psychiatry 2014; 85 (3) 319-325
    CrossrefPubMedGoogle Scholar